Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM). On 29 March 2018, Kazia announced that it had initiated its Phase II clinical trial where GDC-0084 would be studied in patients with GBM. In the video below, we explain what GBM is and how, since GDC-0084 was designed from the ground up as a brain cancer drug, it will cross the blood brain barrier for the treatment of brain tumours.
Related announcement: Novel Australian drug GDC-0084 for glioblastoma brain cancer starts Phase II clinical trial in US.
“The need for new therapies for glioblastoma remains immense - clinical trials of a variety of potential new therapies are ongoing, but we haven’t yet seen a very convincing new treatment option emerge,” said Dr James Garner, Kazia Therapeutics CEO and Executive Director.
“One reason is that many of the drugs being tried are really intended for use in other tumour types, and are only tested in glioblastoma via small and speculative clinical trials."
“We are excited to now have the trial of GDC-0084 underway, and look forward to working with the participating clinicians.”
More about GDC-0084
